Scholarlink

<p>Triggering protease-activated cell death is a promising strategy for cancer treatment. Here, we used phage-assisted evolution to reprogram botulinum neurotoxin serotype X proteases to cleave and activate procaspase-1 and gasdermin D, key effectors of inflammatory cell death. We also developed an efficient system to broadly characterize the substrate specificity of wild-type and evolved botulinum neurotoxin serotype X protease variants. Evolved proteases triggered robust cell death across multiple cancer cell lines. The gasdermin D-cleaving protease exclusively induced lytic death, whereas the procaspase-1-cleaving variant initiated both lytic and apoptotic cell death. To enable self-delivery into mammalian cells, we reconstitute evolved proteases with a native BoNT translocation domain, selectively killing cultured cancer cells while sparing non-cancerous cells. Expression of the evolved protease targeting caspase-1 reduced tumor growth in a highly drug-resistant tumor mouse model. These findings establish an evolving protease system to modulate inflammatory cell death and highlight the potential of BoNT proteases as programmable tools for targeted cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evolution of botulinum neurotoxin serotype X proteases to induce inflammatory cell death in cancer cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月3日

查看全文
  • Julia McCreary,
  • Colin F. Hemez,
  • Michael H. Raymond,
  • Travis R. Blum,
  • Angel Gonzalez-Valero,
  • Teresa L. Augustin,
  • Nicholas A. Krasnow,
  • Stephan J. DeCarlo,
  • Yan Qin,
  • Kaitlin Rhee,
  • Wei Jiang,
  • Blanche C. Ip,
  • Ahmad S. Khalil,
  • David R. Liu

摘要

Triggering protease-activated cell death is a promising strategy for cancer treatment. Here, we used phage-assisted evolution to reprogram botulinum neurotoxin serotype X proteases to cleave and activate procaspase-1 and gasdermin D, key effectors of inflammatory cell death. We also developed an efficient system to broadly characterize the substrate specificity of wild-type and evolved botulinum neurotoxin serotype X protease variants. Evolved proteases triggered robust cell death across multiple cancer cell lines. The gasdermin D-cleaving protease exclusively induced lytic death, whereas the procaspase-1-cleaving variant initiated both lytic and apoptotic cell death. To enable self-delivery into mammalian cells, we reconstitute evolved proteases with a native BoNT translocation domain, selectively killing cultured cancer cells while sparing non-cancerous cells. Expression of the evolved protease targeting caspase-1 reduced tumor growth in a highly drug-resistant tumor mouse model. These findings establish an evolving protease system to modulate inflammatory cell death and highlight the potential of BoNT proteases as programmable tools for targeted cancer therapy.